LR-M category tied to lower survival in HCC resection patients
Non-liver cancer-specific malignant lesions (LR-M) on CT or MRI are tied to lower overall survival in patients with solitary hepatocellular carcinoma (HCC) undergoing resection, a study published February 27 in Radiology found. Researchers led by Roberto Cannella, MD, from the University of Palermo in Italy also found that the presence of at least one non-targetoid feature is linked to increased recurrence risk, regardless of LI-RADS category. “Overall, our results confirm that the LR-M category should be considered in addition to pathology,” Cannella and colleagues wrote. The Liver Imaging Reporting and Data System...
Source: AuntMinnie.com Headlines - February 27, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: CT MRI Source Type: news

Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis - Miwa T, Hanai T, Hirata S, Nishimura K, Unome S, Nakahata Y, Imai K, Shirakami Y, Suetsugu A, Takai K, Shimizu M.
This study aimed to determine the relationship between animal naming test (ANT), falls, and fall-related fractures in patients with cirrhosis. Cognitive impairment and frailty were assessed using ANT and Karnofsky performance status (KPS), respectively. Fa... (Source: SafetyLit)
Source: SafetyLit - February 26, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Undiagnosed Cirrhosis May Underlie Some Dementia Cases Undiagnosed Cirrhosis May Underlie Some Dementia Cases
Some US veterans diagnosed with dementia may have undiagnosed advanced fibrosis or cirrhosis that could explain their cognitive impairment.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - February 16, 2024 Category: Psychiatry Tags: Gastroenterology Source Type: news

Income inequality and deaths of despair risk in Canada, identifying possible mechanisms - Loverock A, Benny C, Smith BT, Siddiqi A, Pabayo R.
BACKGROUND: Declines in life expectancy in developed countries have been attributed to increases in drug-related overdose, suicide, and liver cirrhosis, collectively referred to as deaths of despair. Income inequality is proposed to be partly responsible f... (Source: SafetyLit)
Source: SafetyLit - February 5, 2024 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Missed, Undiagnosed Cirrhosis May Be Risk Factor for Cognitive Decline
FRIDAY, Feb. 2, 2024 -- Missed or undiagnosed cirrhosis may be a risk factor for cognitive decline, according to a study published online Jan. 31 in JAMA Network Open.Jasmohan S. Bajaj, M.D., from Virginia Commonwealth University in Richmond, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2024 Category: Pharmaceuticals Source Type: news

Could Many Cases of'Dementia' in Men Be Liver Cirrhosis Instead?
THURSDAY, Feb. 1, 2024 -- A new study of aging U.S. veterans finds that one in every 10 who have been diagnosed with dementia might actually have brain impairments caused by liver cirrhosis.It ' s a condition called hepatic encephalopathy, and it ' s... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 1, 2024 Category: General Medicine Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

Mushroom poisoning: a rare etiology of acute liver failure - Mohammed HMI, Ahmad F.
Acute liver failure is defined as a rapid deterioration in liver function, manifested by symptoms and signs of hepatic encephalopathy and disturbed synthetic function in a patient without  Pre-existing cirrhosis and with an illness of less than 26 weeks dur... (Source: SafetyLit)
Source: SafetyLit - January 31, 2024 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Antivirals Aid HBeAg-Negative Chronic Hepatitis B Patients
WEDNESDAY, Jan. 3, 2024 -- Continuous nucleos(t)ide analog treatment is effective in lowering the risk for liver cirrhosis in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients, according to a study published in the December... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2024 Category: Pharmaceuticals Source Type: news

LI-RADS shows low NPV in per-patient liver tumor assessment
Per-patient grouping for liver tumor status based on LI-RADS and treatment response shows low negative predictive value (NPV) in detecting residual or untreated tumors, according to research published December 19 in Radiology.  A team led by Omar Hassan, MD, from the University of California, San Francisco studied hepatocellular carcinoma (HCC) patients who underwent local-regional therapy followed by liver transplant. The team found that per-patient stratification of tumor status at either pretransplant CT or MRI based on the LI-RADS version 2018 treatment response algorithm showed low NPV in this area. “The relativel...
Source: AuntMinnie.com Headlines - December 20, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: MRI Abdominal Imaging Source Type: news

Screening for Alcohol Use Disorder Cuts Hospital Readmission Screening for Alcohol Use Disorder Cuts Hospital Readmission
About half of actively drinking patients hospitalized for alcohol-associated hepatitis or decompensated alcohol-related cirrhosis undergo an intervention that can improve outcomes.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 15, 2023 Category: Internal Medicine Tags: Gastroenterology Source Type: news

Taste, Smell Changes Affect QOL in Patients With Cirrhosis Taste, Smell Changes Affect QOL in Patients With Cirrhosis
Clinicians should screen for changes in taste and smell among patients at risk for cognitive changes and offer nutritional interventions to support body weight and QOL.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 6, 2023 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Markers of Inflammation Can Predict 180-Day Mortality in Cirrhosis
TUESDAY, Dec. 5, 2023 -- For patients with newly diagnosed cirrhosis, markers of inflammation can predict 180-day mortality, but not liver-related admissions, according to a study published online Nov. 16 in Scientific Reports.Thit Mynster... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2023 Category: Pharmaceuticals Source Type: news

89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
89bio Inc ETNB announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in nonalcoholic steatohepatitis (NASH). The program will include two Phase 3 trials evaluating patients with NASH: • ENLIGHTEN-Cirrhosis trial will enroll patients with…#incetnb #fda #phase3 #enlightencirrhosis #f2f3 #ema #enlightenfibrosis #glp1 (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news